Tree pollen allergy immunotherapy - Lofarma
Alternative Names: Carbamylated monomeric tree pollen drops; LAIS Birch-Alder tablets; Lais Frühblüher sublingual drops; Tree-pollen allergoid - LofarmaLatest Information Update: 28 Sep 2021
At a glance
- Originator Lofarma S.p.A
- Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinoconjunctivitis
Most Recent Events
- 28 Sep 2021 Tree pollen allergy immunotherapy is still in phase III trials for Allergic rhinoconjunctivitis in Italy (Lofarma website, September 2021)
- 28 Sep 2021 Launched for Allergic rhinoconjunctivitis (In the elderly, Prevention, In adults) in Germany (Sublingual) (Lofarma website, September 2021)
- 28 Sep 2021 Launched for Allergic rhinoconjunctivitis (Prevention) in Germany (Sublingual) (Lofarma website, September 2021)